PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Temozolomide (TMZ) is a standard chemotherapy for glioblastoma (GBM), but its efficacy is limited by intrinsic or acquired resistance.
• Identifying novel therapeutic targets to overcome TMZ resistance is crucial for improving patient outcomes in GBM.

Purpose of the Study:

• To investigate the role of Polo-like kinase 4 (PLK4) in regulating GBM sensitivity to temozolomide (TMZ).
• To elucidate the molecular mechanisms by which PLK4 influences TMZ resistance.
• To evaluate the therapeutic potential of targeting PLK4 in combination with TMZ for GBM treatment.

Main Methods:

• Analysis of PLK4 mRNA levels in relation to glioma grade and patient survival.
• In vitro studies assessing TMZ sensitivity in GBM cells with altered PLK4 expression.
• In vivo studies using a GBM mouse model to evaluate the combination of PLK4 inhibition and chemotherapy.
• Investigation of the interaction between PLK4, IKBKE, and NF-κB signaling.

Main Results:

• PLK4 mRNA levels correlated with glioma grade progression and inversely with overall survival in high-grade glioma patients.
• Overexpression of PLK4 decreased TMZ sensitivity in GBM cells, while PLK4 depletion enhanced it.
• Inhibition of PLK4 combined with chemotherapy slowed tumor growth and improved survival in a GBM mouse model.
• PLK4 phosphorylates IKBKE, activating NF-κB transcriptional activity and promoting anti-apoptosis.
• The PLK4 inhibitor CFI400945 showed synergistic effects with TMZ in patient-derived GBM xenografts.

Conclusions:

• PLK4 is a key regulator of TMZ sensitivity in GBM through the PLK4-IKBKE/NF-κB signaling axis.
• Therapeutic targeting of PLK4 can enhance the anti-tumor effects of TMZ and improve outcomes in GBM.
• PLK4 inhibition represents a promising strategy to overcome chemoresistance in glioblastoma.